New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
08:05 EDTJNJJanssen-Cilag says Olysio receives marketing authorization in the EU
Janssen-Cilag International NV announced that its next generation protease inhibitor OLYSIO has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C, in combination with other medicinal products.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
08:12 EDTJNJJ&J granted orphan status for acute myeloid leukemia treatment
The FDA granted Johnson & Johnson unit Janssen Research orphan status for its acute myeloid leukemia treatment.
May 4, 2015
07:35 EDTJNJNewYorkBio to hold a conference
Subscribe for More Information
May 3, 2015
18:11 EDTJNJSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
07:43 EDTJNJExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 29, 2015
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
April 27, 2015
06:19 EDTJNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use